SEC Comment Letter for XENOPORT INC (CIK 0001130591) — May 20, 2005
XENOPORT INC (CIK 0001130591)
Date: May 20, 2005 · CIK: 0001130591 · Accession: 0000000000-05-025018
AI Filing Summary & Sentiment
File numbers found in text: 333-122156
Letter
Mail Stop 3-09 May 20, 2005 Ronald W. Barrett, Ph.D. Chief Executive Officer XenoPort, Inc. 3410 Central Expressway Santa Clara, CA 95051
Re: Xenoport, Inc. Amendment No. 3 to the Registration Statement on Form S-1 File No. 333-122156
Dear Dr. Barrett:
We have reviewed your filing and have the following comments. Where indicated, we think you should revise your document in response to these comments. If you disagree, we will consider your explanation as to why our comment is inapplicable or a revision is unnecessary. Please be as detailed as necessary in your explanation.
Please understand that the purpose of our review process is to assist you in your compliance with the applicable disclosure requirements and to enhance the overall disclosure in your filing. We look forward to working with you in these respects. We welcome any questions you may have about our comments or on any other aspect of our review. Feel free to call us at the telephone numbers listed at the end of this letter.
Form S-1
Management`s Discussion and Analysis of Financial Condition and Results..., page 35
Research and Development, page 40 1. We`ve reviewed your revisions in response to our April 18, 2005 letter. Due to its materiality, we feel that a discussion of "research and preclinical" costs is appropriate. Please disclose the nature of such costs and quantify those costs by major functional classification (e.g. employee related expenses and facilities costs). Also disclose the effect that "research and preclinical" will have on future operations and cash flows.
* * *
Provide a letter keying your responses to the comments. If you believe complying with these comments is not appropriate, tell us why in your letter. The response letter should be uploaded to EDGAR, with the form type label "CORRESP" and linked to the registration statement file number. We may have comments after reviewing revised materials and your responses.
Submit your request for acceleration at least two business days prior to the requested effective date.
You may contact Keira Ino at (202) 551-3659 or James Rosenberg (202) 551-3679 if you have questions regarding comments on the financial statements and related matters. Please contact Song Brandon at (202) 551-3621 or John Krug at (202) 551-3862 with any other questions.
Sincerely,
Jeffrey Riedler
Assistant Director
Show Raw Text
<DOCUMENT>
<TYPE>LETTER
<SEQUENCE>1
<FILENAME>filename1.txt
<TEXT>
Mail Stop 3-09
May 20, 2005
Ronald W. Barrett, Ph.D.
Chief Executive Officer
XenoPort, Inc.
3410 Central Expressway
Santa Clara, CA 95051
Re: Xenoport, Inc.
Amendment No. 3 to the Registration Statement on Form S-1
File No. 333-122156
Dear Dr. Barrett:
We have reviewed your filing and have the following
comments.
Where indicated, we think you should revise your document in
response
to these comments. If you disagree, we will consider your
explanation as to why our comment is inapplicable or a revision is
unnecessary. Please be as detailed as necessary in your
explanation.
Please understand that the purpose of our review process is
to
assist you in your compliance with the applicable disclosure
requirements and to enhance the overall disclosure in your filing.
We look forward to working with you in these respects. We welcome
any questions you may have about our comments or on any other
aspect
of our review. Feel free to call us at the telephone numbers
listed
at the end of this letter.
Form S-1
Management`s Discussion and Analysis of Financial Condition and
Results..., page 35
Research and Development, page 40
1. We`ve reviewed your revisions in response to our April 18, 2005
letter. Due to its materiality, we feel that a discussion of
"research and preclinical" costs is appropriate. Please disclose
the
nature of such costs and quantify those costs by major functional
classification (e.g. employee related expenses and facilities
costs).
Also disclose the effect that "research and preclinical" will have
on
future operations and cash flows.
* * *
Provide a letter keying your responses to the comments. If
you
believe complying with these comments is not appropriate, tell us
why
in your letter. The response letter should be uploaded to EDGAR,
with the form type label "CORRESP" and linked to the registration
statement file number. We may have comments after reviewing
revised
materials and your responses.
Submit your request for acceleration at least two business
days
prior to the requested effective date.
You may contact Keira Ino at (202) 551-3659 or James
Rosenberg
(202) 551-3679 if you have questions regarding comments on the
financial statements and related matters. Please contact Song
Brandon at (202) 551-3621 or John Krug at (202) 551-3862 with any
other questions.
Sincerely,
Jeffrey Riedler
Assistant Director
cc: Suzanne Sawochka Hooper, Esq.
Kathryn Walker Hall, Esq.
Cooley Godward LLP
Five Palo Alto Square
3000 El Camino Real
Palo Alto, CA 94306
??
??
??
??
1
</TEXT>
</DOCUMENT>